Applying NGS Data to Find Evolutionary Network Biomarkers from the Early and Late Stages of Hepatocellular Carcinoma

Figure 3

Overview of significant pathways in network marker of total stage of liver cancer. Among KEGG pathways identified via the DAVID tool (Table 4) showing significant associations with specific proteins of the early stage of liver cancer, these molecular pathways had values of ≤0.05. This indicates that these pathways play important roles in the carcinogenesis mechanism in the early stage of liver cancer. The network markers of the early stage of liver cancer highlighted by stars show potentially targets in the pathways. Due to the different naming systems, the same proteins in these tables and in the text are labeled with different names.

(a) The proteins in the total stage liver cancer network marker are enriched in “hsa04110:Cell cycle” (Rank 1 in Table 6)

(b) The proteins in the total stage liver cancer network marker are enriched in “hsa04114:Oocyte meiosis” (Rank 3 in Table 6)

(c) The proteins in the total stage liver cancer network marker are enriched in “hsa03030:DNA replication” (Rank 4 in Table 6)

(d) The proteins in the total stage liver cancer network marker are enriched in “hsa05200:Pathways in cancer” (Rank 5 in Table 6)

(e) The proteins in the total stage liver cancer network marker are enriched in “hsa04115:p53 signaling pathway” (Rank 11 in Table 6)

(f) The proteins in the total stage liver cancer network marker are enriched in “h_g1Pathway:Cell Cycle: G₁/S Check Point” (Rank 1a in Table 6) (BioCarta)

(g) The proteins in the total stage liver cancer network marker are enriched in “h_p27Pathway:Regulation of p27 Phosphorylation during Cell Cycle Progression” (Rank 2a in Table 6) (BioCarta)

(h) The proteins in the total stage liver cancer network marker are enriched in “h_p53Pathway:p53 Signaling Pathway” (Rank 3a in Table 6) (BioCarta)

(i) The proteins in the total stage liver cancer network marker are enriched in “h_her2Pathway:Role of ERBB2 in Signal Transduction and Oncology” (Rank 4a in Table 6) (BioCarta)